(Pink Sheets: BDGW), (Pink Sheets: JCDS), (OTCBB: IXSBF), (OTCBB: AYXC).

Turning Pennies into dollars: (Pink Sheets: BDGW), (Pink Sheets: JCDS), (OTCBB: IXSBF), (OTCBB: AYXC).

Are you a public company looking for exposure?
Contact RealPennies.com - 1.800.940.6559

For more info: http://bdgw.realpennies.com

Budget Waste Inc. (Pink Sheets: BDGW) (February 7th, 2008) announced that it is proposing to open and operate a new waste recycling facility in the Calgary area.

In order to increase the total volume of recycled material processed by BWI, a new material recycling facility (MRF) is planned by the management of BWI. This facility will have several unique features incorporated into the design and layout of the plant. Some of these features include multiple waste stream processing, advanced post sort processing capabilities, and the ability to produce finished products from sorted recyclables.

As there are no recycling facilities of this type in this area, BWI has recognized the opportunity to step into this market. BWI has management in place with vast experience in the operation of such a facility. Several people on the management team have been instrumental in bringing recycling to the area by having involvement in successful pilot projects in both the private and municipal levels. They have also been directly involved in the startup and operation of several recycling programs.

The facility is currently in the planning and layout phase and is anticipated to be fully operational by mid to late 2008.

Budget Waste Inc. is a waste solutions company in Western Canada providing complete waste and recycling services to commercial, industrial, construction, homebuilding, oilfield and residential clients. With our broad range of innovative services we offer our customers more value for their dollar and reduce accounting costs by providing streamlined billing. BWI is currently following its growth through acquisition strategy with exceptional success. With regulations throughout North America pressing companies and individuals to be more vigilant in the way they handle their waste products we see vast opportunity for expansion of our distinctive services. We are confidant that Extraordinary growth and focus on customer needs will bring our stockholders outstanding value for the confidence they have placed in BWI.

For more info: http://jcds.realpennies.com

JC Data Solutions, Inc. (Pink Sheets: JCDS) (February 8th, 2008) announced Friday it plans to reduce the company's total outstanding shares. The company is returning to its treasury 250 million common shares.

Cary Allen, JCDS's Chairman and Chief Executive Officer, said, "In an attempt to increase shareholder value we plan to reduce outstanding shares this year. We began the fiscal year with approximately 270 million common shares outstanding and have increased that number to approximately 620 million outstanding shares through insider share distribution. We have reconsidered our position and decided to bring back our outstanding shares to approximately 370 million shares. We are also considering buying back shares in the open market during 2008."

"The future of our company is on the right track," commented Allen. "We have made substantial progress in efforts to position ourselves as a key player in the Healthcare, Oil and Gas and Attorney markets. We expect to be in position by year-end, at the latest, to announce testing applications of our new software that captures processes and reports ACH transaction data for the above stated industries."

For more info: http://ixsbf.realpennies.com

InNexus Biotechnology Inc. (OTCBB: IXSBF) (February 7th, 2008), a drug development company commercializing the next generation of monoclonal antibodies based on its technology, Dynamic Cross Linking (DXL), announced encouraging preliminary results of an in vivo animal study which exhibited DXL625 (CD20)'s efficacy in reducing the growth rate of lymphoma cancer tumors.

Based on data from a recently initiated animal study, preliminary data shows an increase of potency of the company's first product candidate, DXL625 (CD20), for the prospective treatment of non-Hodgkin's lymphoma. The study compared DXL625 with a control vehicle and Genentech's Rituxan. Previous laboratory studies presented as part of the Technology Workshop at the IBC Life Science 18th Annual International Antibody Engineering Conference in San Diego indicated that DXL625 may afford greater potency in killing tumor cells and showed increased binding to the target antigen (CD20) on NHL tumor cells.

Dr. Thomas Kindt, InNexus Biotechnology's Chief Scientific Officer, said, "The preliminary results of these initial tests on DXL625 are exciting data corroborating our work to date and providing opportunities of exploration and use of DXL technology. Studies done at InNexus have also discovered that DXL625 has greater killing potency than Rituxan in cell lines of both moderate and low expressors of CD20, the target used to attack NHL."

Additional results demonstrated DXL625 more potently induced apoptosis (cell suicide) in B-cell lymphoma cells and B-cell leukemia (Hairy Cells).

"Boosting new and proven monoclonal antibody products will yield critical medical and commercial advantages, making a growing multi-billion dollar product category even better," said Jeff Morhet, Chairman and CEO of InNexus Biotechnology. "Our proof of principle demonstration suggests that DXL capabilities can be applied to a diverse range of late stage and prospective treatments. The data are an important example of how InNexus can improve candidates, with possible advances in product life cycles, dosing, product stability, and other key parameters."

For more info: http://ayxc.realpennies.com

Alynx, Co. (OTCBB: AYXC) (February 8th, 2008) announced Friday it has completed its acquisition of 100% of the outstanding shares of MiMedx, Inc., a development-stage medical device company, based in Tampa, Florida.

In connection with the transaction, structured as a reverse merger, Alynx issued approximately 52.9 million new shares of its common stock, and approximately 3.7 million new shares of its preferred stock (convertible into approximately 56.9 million shares of its common stock, subject to specified conditions). Also in connection with the merger, Alynx repurchased and canceled 20.0 million shares of its outstanding common stock. After the merger, there is a total of approximately 55.8 million shares of common stock and 3.7 million shares of preferred stock of Alynx outstanding, with former MiMedx shareholders holding approximately 97.25% on a fully-diluted basis. The shares issued in the merger were issued pursuant to a private placement and are not presently eligible for resale to the public.

The executive officers and directors of MiMedx became the executive officers and directors of Alynx after the merger. The board of Alynx has expressed its intention to call a meeting of shareholders in the near future. One of the purposes of the meeting would include a proposal to approve a reverse stock split of approximately one-for-three for each share of Alynx common stock, reducing the total shares outstanding to approximately 36.5 million shares. If the board calls a meeting of shareholders, appropriate filings would be made with the SEC and proxy materials would be provided to Alynx shareholders, who would then have the opportunity to consider and vote upon the proposal. There can be no assurance that the proposal will be submitted, and if submitted, the proposal may vary from the proposals presently contemplated. Furthermore, there can be no assurance the proposal will be approved by the shareholders.

Read our full disclaimer at: http://www.realpennies.com/start.html

Investors are advised that this analysis is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. This report does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this information. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Past performance is no guarantee of future results. Please consult a broker before purchasing or selling any securities mentioned on RealPennies. For more movers: http://www.realpennies.com/wrapup.html

Any opinions expressed herein are statements of our judgment as of the date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html

Sponsored by: http://www.isthemarketopen.com

RealPennies .

Telephone: 1-800-940-6559

Matt /at/ realpennies.com